PALATIN TECHNOLOGIES INC
PTNT CIK: 0000911216
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation NJ
Business Address 4B CEDAR BROOK DRIVE, CRANBURY, NJ, 08512
Mailing Address 4B CEDAR BROOK DRIVE, CRANBURY, NJ, 08512
Phone 609-495-2200
Fiscal Year End 0630
EIN 954078884
Financial Overview
FY2025
-$111K
Stockholders' Equity
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | January 2, 2026 | View on SEC |
| 4 Insider stock transaction report | January 2, 2026 | View on SEC |
| 4 Insider stock transaction report | December 29, 2025 | View on SEC |
| 8-K/A Current report amendment | December 19, 2025 | View on SEC |
| 4 Insider stock transaction report | December 11, 2025 | View on SEC |
| 4 Insider stock transaction report | December 11, 2025 | View on SEC |
| 4 Insider stock transaction report | December 11, 2025 | View on SEC |
| 4 Insider stock transaction report | December 11, 2025 | View on SEC |
| 4 Insider stock transaction report | December 11, 2025 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | December 8, 2025 | View on SEC |
Annual Reports
10-K September 23, 2025
- Phase 3 trial completed for PL9643 dry eye treatment
- Obesity drug shows combo potential with weight-loss meds like Mounjaro
Insider Trading
SELL 1 insiders
1 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.